MiMedx Group Inc
$ 3.43
-11.60%
16 Apr - close price
- Market Cap 509,583,000 USD
- Current Price $ 3.43
- High / Low $ 3.92 / 3.31
- Stock P/E 10.72
- Book Value 1.73
- EPS 0.32
- Next Earning Report 2026-04-29
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA 0.13 %
- ROE 0.22 %
- 52 Week High 7.99
- 52 Week Low 3.31
About
MiMedx Group, Inc. develops and distributes placental tissue allografts for various sectors of healthcare. The company is headquartered in Marietta, Georgia.
Analyst Target Price
$9.67
Quarterly Earnings
| Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2026-03-04 | 2025-10-29 | 2025-07-29 | 2025-04-28 | 2025-02-26 | 2024-10-30 | 2024-07-31 | 2024-04-30 | 2024-02-28 | 2023-10-30 | 2023-08-01 | 2023-05-02 |
| Reported EPS | 0.14 | 0.15 | 0.1 | 0.05 | 0.07 | 0.05 | 0.12 | 0.07 | 0.32 | 0.06 | -0.0046 | -0.06 |
| Estimated EPS | 0.0929 | 0.06 | 0.054 | 0.055 | 0.075 | 0.04 | 0.08 | 0.05 | 0.07 | 0.05 | -0.02 | -0.09 |
| Surprise | 0.0471 | 0.09 | 0.046 | -0.005 | -0.005 | 0.01 | 0.04 | 0.02 | 0.25 | 0.01 | 0.0154 | 0.03 |
| Surprise Percentage | 50.6997% | 150% | 85.1852% | -9.0909% | -6.6667% | 25% | 50% | 40% | 357.1429% | 20% | 77% | 33.3333% |
Next Quarterly Earnings
| Mar 2026 | |
|---|---|
| Reported Date | 2026-04-29 |
| Fiscal Date Ending | 2026-03-31 |
| Estimated EPS | -0.03 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: MDXG
2026-04-16 13:50:06
MiMedx Group, Inc. announced the departure of Ricci Whitlow as Chief Operating Officer, effective April 14, 2026. This change is part of a cost-reduction initiative aimed at prioritizing growth, streamlining operations, and significantly reducing operating expenses. Ms. Whitlow's departure was not due to a disagreement with the company.
2026-04-16 13:40:07
MiMedx Group, Inc. announced a restructuring plan that includes eliminating the Chief Operating Officer position and implementing cost reduction measures expected to save approximately $40 million. The company projects a one-time restructuring charge of about $4 million in the second quarter of 2026. This move aims to streamline operations, prioritize growth in its flourishing surgical business, and lessen the impact of slow recovery in the wound care business due to Medicare reimbursement reductions.
2026-04-16 12:40:07
MiMedx Group (NASDAQ: MDXG) implemented a cost reduction initiative on April 14, 2026, eliminating the chief operating officer position and reducing executive compensation. Ricci Whitlow, the former COO, departed immediately. CEO Joe Capper's base salary was cut by 20%, and other executive salaries were reduced by 10% through December 31, 2026, to streamline operations and cut expenses.
2026-04-16 11:40:07
MiMedx (MDXG) announced a restructuring plan to cut approximately $40 million in annual operating expenses and expects a one-time $4 million restructuring charge in Q2 2026. The company eliminated the Chief Operating Officer role, stating that while its Surgical business will receive further investment, the Wound Care business is recovering slowly due to a January 1 Medicare reimbursement reduction. Following the announcement, MDXG's stock declined by 12.34%, reflecting a significant negative market reaction despite the cost-saving initiatives.
2026-04-16 11:40:06
MiMedx Group (NASDAQ: MDXG) has initiated a restructuring and cost reduction plan targeting approximately $40 million in annualized operating expense savings. This move comes as its Wound Care business is experiencing a slow recovery following a January 1 Medicare reimbursement reduction, although its Surgical business continues to perform well. As part of the plan, the Chief Operating Officer position has been eliminated, and executive base salaries have been reduced, with a one-time restructuring charge of about $4 million expected in Q2 2026.
2026-04-16 11:40:06
MIMEDX announced a restructuring and cost reduction initiative to streamline operations and prioritize growth opportunities, expecting to save approximately $40 million annually. This includes the elimination of the Chief Operating Officer position, held by Ricci Whitlow, and a one-time restructuring charge of about $4 million in Q2 2026. The changes are primarily due to a slower-than-expected recovery in the Wound Care business following a January 1st Medicare reimbursement reduction.
